Clinical trials of PCSK9 inhibitors to assess their effect on cardiovascular outcomes are ongoing, but reliable evidence for a possible association between PCSK9 inhibition and risk of diabetes could take longer to accrue. This evidence concerns the gene PCSK9 and diabetes mellitus.